GSK's Tyverb only to be used in clinical trials for breast cancer patients, says NICE
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for health and Clinical Excellence, still says that GlaxoSmithKline's anticancer Tyverb (lapatinib) is not value for money and that it should only be used to treat NHS patients in England and Wales with advanced or metastatic breast cancer as part of a clinical trial.